SCHEMBL3539357

SCHEMBL3539357

CCC(CC)NC(=O)C1=CC2(CCN(C(=O)OC(C)(C)C)CC2)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.47
TSHR P16473 2/20 0.45
ALOX15 P16050 1/20 0.45
PDK2 Q15119 1/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
HDAC8 Q9BY41 2/20 0.42
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
KDM1A O60341 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
PDK4 Q16654 1/20 0.38
TACR1 P25103 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538217 0.91 KDM4E (0.41) ATMTSHRALOX15PDK2KDM4E
SCHEMBL3540887 0.86 PDK2 (0.46) ATMTSHRALOX15PDK2HDAC1
SCHEMBL6588671 0.82 PDK2 (0.47) ATMTSHRALOX15PDK2HDAC1
SCHEMBL1222505 0.82 PDK2 (0.48) ATMTSHRALOX15PDK2HDAC1
SCHEMBL7624926 0.82 PDK2 (0.45) ATMTSHRALOX15PDK2HDAC1
SCHEMBL12990833 0.81 KCNH2 (0.36) KDM4EOPRK1
SCHEMBL12990573 0.81 L3MBTL1 (0.38) ALOX15PDK2KDM4ECHRM2CHRM4
SCHEMBL12990515 0.81 L3MBTL1 (0.46) ALOX15KDM4ECHRM2CHRM4CHRM1
SCHEMBL12991334 0.78 L3MBTL1 (0.40) ALOX15CHRM2CHRM4CHRM1CHRM3
SCHEMBL12991081 0.78 CCR2 (0.36) ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858790-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-28 US disclosed
US-7858790-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-28 US disclosed
US-7858790-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-28 US disclosed
US-20080033002-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-02-07 US disclosed
US-20080033002-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-02-07 US disclosed
US-20080033002-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2008-02-07 US disclosed
WO-2008005295-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033002-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 ATM 2394/4885TSHR 131/4885ALOX15 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.